11/18
08:31 am
sava
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer [Yahoo! Finance]
Low
Report
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer [Yahoo! Finance]
11/18
08:30 am
sava
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
Low
Report
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
11/15
11:54 am
sava
Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
Medium
Report
Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
11/12
02:02 pm
sava
What Makes Cassava Sciences (SAVA) a New Buy Stock [Yahoo! Finance]
Low
Report
What Makes Cassava Sciences (SAVA) a New Buy Stock [Yahoo! Finance]
11/8
02:32 pm
sava
Cassava Sciences, Inc. (NASDAQ: SAVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $116.00 price target on the stock.
Medium
Report
Cassava Sciences, Inc. (NASDAQ: SAVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $116.00 price target on the stock.
11/7
08:08 am
sava
Cassava Sciences Reports Q3 2024 Financial and Operating Results [Yahoo! Finance]
Medium
Report
Cassava Sciences Reports Q3 2024 Financial and Operating Results [Yahoo! Finance]
11/7
07:55 am
sava
Cassava Sciences Reports Q3 2024 Financial and Operating Results
Medium
Report
Cassava Sciences Reports Q3 2024 Financial and Operating Results
10/31
08:30 am
sava
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
Low
Report
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
10/15
08:19 pm
sava
Lightning Round: Stay away from Mobileye, says Jim Cramer [CNBC]
Medium
Report
Lightning Round: Stay away from Mobileye, says Jim Cramer [CNBC]
10/8
11:13 am
sava
What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday? [Yahoo! Finance]
High
Report
What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday? [Yahoo! Finance]
10/8
08:37 am
sava
Cassava Sciences, Inc. (NASDAQ: SAVA) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $116.00 price target on the stock.
Low
Report
Cassava Sciences, Inc. (NASDAQ: SAVA) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $116.00 price target on the stock.
10/2
11:07 am
sava
Cassava's Alzheimer's Therapy: A Confidence Bet [Seeking Alpha]
Low
Report
Cassava's Alzheimer's Therapy: A Confidence Bet [Seeking Alpha]
9/30
11:04 am
sava
Company News for Sep 30, 2024 [Yahoo! Finance]
Medium
Report
Company News for Sep 30, 2024 [Yahoo! Finance]
9/27
06:23 pm
sava
Why Cassava Sciences Stock Dived by Almost 11% Today [Yahoo! Finance]
Medium
Report
Why Cassava Sciences Stock Dived by Almost 11% Today [Yahoo! Finance]
9/27
03:42 pm
sava
Cassava Sciences agrees to $40M SEC fine over Alzehimer's claims [Yahoo! Finance Canada]
Low
Report
Cassava Sciences agrees to $40M SEC fine over Alzehimer's claims [Yahoo! Finance Canada]
9/27
10:32 am
sava
Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims [Yahoo! Finance]
Low
Report
Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims [Yahoo! Finance]
9/27
08:58 am
sava
Cassava Sciences shares drop in pre-open trade after $40 mln SEC settlement [Yahoo! Finance]
Low
Report
Cassava Sciences shares drop in pre-open trade after $40 mln SEC settlement [Yahoo! Finance]
9/27
08:36 am
sava
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty [Yahoo! Finance]
Low
Report
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty [Yahoo! Finance]
9/27
05:59 am
sava
Cassava settles SEC charges related to Alzheimer's candidate for $40M [Seeking Alpha]
Low
Report
Cassava settles SEC charges related to Alzheimer's candidate for $40M [Seeking Alpha]
9/26
06:15 pm
sava
Cassava Sciences Resolves SEC Investigation
Low
Report
Cassava Sciences Resolves SEC Investigation
9/25
04:40 pm
sava
Cassava's Simufilam: Safe On The Outside, Scrambled On The Inside [Seeking Alpha]
Medium
Report
Cassava's Simufilam: Safe On The Outside, Scrambled On The Inside [Seeking Alpha]
9/24
08:48 am
sava
Cassava Sciences' on-going late stage trials for Alzheimer's treatment gets DSMB nod [Seeking Alpha]
Medium
Report
Cassava Sciences' on-going late stage trials for Alzheimer's treatment gets DSMB nod [Seeking Alpha]
9/24
08:30 am
sava
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
Medium
Report
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
9/9
10:31 am
sava
Cassava Sciences' Richard Barry to take helm as permanent CEO [Seeking Alpha]
Low
Report
Cassava Sciences' Richard Barry to take helm as permanent CEO [Seeking Alpha]
9/9
08:30 am
sava
Cassava Sciences Names Rick Barry as Chief Executive Officer
Low
Report
Cassava Sciences Names Rick Barry as Chief Executive Officer